Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06027086RecruitingPhase 1/Phase 2
Combination drug therapy for advanced fibrolamellar carcinoma
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
Baltimore, MarylandAges 12 years+ - NCT06049355RecruitingPhase 2
Exercising together during radiation for prostate or breast cancer
This trial tests if partner-supported strength training during radiation therapy helps survivors stay active. You and your spouse or partner will do supervised exercise sessions from home via video calls.
Portland, OregonAges 18 years+ - NCT06051760RecruitingPhase 1
NV-001 for advanced solid tumors after standard treatments
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06053658RecruitingPhase 2
Tivozanib and Nivolumab for advanced kidney cancer
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
Irvine, CaliforniaAges 18 years+ - NCT06055816RecruitingPhase 2
Gemcitabine plus two targeted drugs for older adults with nasopharyngeal cancer
This trial tests a combination of three drugs—chemotherapy (gemcitabine), a blood-vessel blocker (Endostar), and an immunotherapy (Envafolimab)—for older adults with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard care for patients aged 65 and up.
Hangzhou, ZhejiangAges 65 years+ - NCT06059963Recruiting
Simple blood test for colorectal cancer screening
This study is testing a new blood test (Signal-C) to see if it can help find colorectal cancer early. You may be able to join if you are average risk and getting a routine screening colonoscopy.
Raonoke, VirginiaAges 45–84 - NCT06063681RecruitingPhase 1
Testing a new ENPPI inhibitor for advanced solid tumors
This trial tests a new drug, SR-8541A, that blocks an enzyme called ENPPI, which may help slow or stop tumor growth. It is for people with advanced or metastatic solid tumors who have not responded to other treatments or have no standard options.
Randwick, New South WalesAges 18 years+ - NCT06067295Recruiting
Long-term study of advanced prostate cancer
This study follows men with advanced prostate cancer that has spread to other parts of the body. It aims to learn more about how the disease and treatments affect patients over time, so doctors can improve care.
Los Angeles, CaliforniaAges 18 years+ - NCT06074692RecruitingPhase 2
PARP inhibitor, SBRT, and immunotherapy for advanced sarcoma
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 10–70 - NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100 - NCT06078384RecruitingPhase 2
Pembrolizumab and chemo for early-stage triple-negative breast cancer
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
AmiensAges 18 years+ - NCT06085755RecruitingPhase 1/Phase 2
Combination drug therapy for HER2-low stomach cancer
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
SeoulAges 19 years+ - NCT06093061RecruitingPhase 2
Maintenance therapy for high-risk nasopharyngeal cancer
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
SingaporeAges 21–99 - NCT06097156Recruiting
Automated blood test for breast cancer monitoring
This trial tests an automated device that prepares blood samples to detect cancer-related changes. It aims to improve how doctors monitor breast cancer that has spread, without needing a tissue biopsy every time.
MilanAges 18 years+ - NCT06108050RecruitingPhase 1
Testing a new drug alone and with pembrolizumab for advanced solid tumors
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Encinitas, CaliforniaAges 18 years+ - NCT06113705Recruiting
Better MRI and blood tests for glioblastoma treatment response
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
RozzanoAges 18 years+ - NCT06127303RecruitingPhase 2
Toripalimab plus cryoablation for lung cancer with limited progression
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06134375RecruitingPhase 1/Phase 2
TM plus capecitabine for triple-negative breast cancer
This trial tests a drug called tetrathiomolybdate (TM) combined with capecitabine for people with triple-negative breast cancer who still have cancer cells after standard chemotherapy and surgery. The goal is to see if this combination can help prevent the cancer from coming back.
Indianapolis, IndianaAges 18–80 - NCT06139107RecruitingPhase 1
Radiation and abemaciclib plus letrozole before breast cancer surgery
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Belleville, New JerseyAges 60 years+ - NCT06141031RecruitingPhase 1
TTI-101 plus radiation for borderline or locally advanced pancreatic cancer
This trial tests a new oral drug (TTI-101) combined with targeted radiation (SBRT) for people with pancreatic cancer that is not removable by surgery. It aims to see if this combination helps shrink tumors that are borderline resectable or locally advanced.
Aurora, ColoradoAges 18 years+ - NCT06141369Recruiting
Personalized mRNA vaccine for advanced endocrine tumors
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06157996RecruitingPhase 2
Lenvatinib, Tislelizumab, and CapeOX for advanced stomach cancer
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06165900RecruitingPhase 2
Radiation plus immunotherapy and chemo before surgery for triple-negative breast cancer
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
Shenyang, LiaoningAges 18–75
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,211 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.